GlassScriptPhysician profile
Iftikhar A Chowdhry
NPI 1154351054
$226,445.91
in general payments reported to CMS, 2019-2025
58 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $14K · 2021: $19K · 2022: $45K · 2023: $33K · 2024: $24K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $18K · Consulting Fee: $8,442 · Honoraria: $8,258 · Travel and Lodging: $3,042 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,205.00 |
| Food and Beverage | $17,657.54 |
| Consulting Fee | $8,441.66 |
| Honoraria | $8,257.50 |
| Travel and Lodging | $3,042.44 |
| Education | $174.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119,751.49 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $32,455.36 | 2019-2025 | Otezla, Tavneos, Enbrel |
| Horizon Therapeutics Plc | $26,492.70 | 2019-2023 | Krystexxa |
| Celgene Corporation | $13,597.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $7,025.71 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $5,638.53 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $5,302.32 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $2,717.33 | 2019-2025 | |
| Pfizer INC. | $2,396.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $993.08 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $937.36 | 2019-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $843.68 | 2021-2025 | Lupkynis |
| Lilly USA, LLC | $841.92 | 2019-2024 | Taltz, Olumiant |
| Mallinckrodt Hospital Products INC. | $827.58 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $600.53 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iftikhar Chowdhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.